Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2011 Mar 9.

Published in final edited form as: J Clin Oncol. 2008 Jun 20;26(18):2959–2965. doi: 10.1200/JCO.2007.15.1928

Table 2.

Testosterone levels (ng/dL) in evaluable patients

	Cohort 1 (6 Cycles)		Cohort 2 (9 Cycles)

	Rising PSA	Metastatic	Rising PSA	Metastatic
	n=25	n=38	n=17	n=21
Baseline, median (range)	354 (210–575)	317 (169–579)	309 (188–466)	316 (148–475)
Peak^a, median (range)	452 (47–898)	462 (148–920)	378 (65–723)	277 (104–732)
Trough^b, median (range)	22 (10–41)	19 (10–38)	12 (10–36)	10 (10–50)

^a

Peak: Day 1 (following testosterone repletion)

^b

Trough: Cohort 1, Day 21 or Cohort 2, Day 19 (before testosterone repletion)